Aura Biosciences, Inc. AURA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -95.6%-22.0pp | -73.5%-9.3pp | -64.3%-8.9pp | -55.4%+0.9pp | -56.2%-10.2pp | |
| Return on assets | -76.7%-16.4pp | -60.3%-6.5pp | -53.9%-5.9pp | -48%+0.5pp | -48.5%-8.8pp | |
| Return on invested capital | -160.7%-64.2pp | -96.5%-19.7pp | -76.8%+5.0pp | -81.8%-15.4pp | -66.3%-10.4pp | |
| Liquidity | ||||||
| Current ratio | 7.1×-1.1× | 8.1×-0.9× | 9×-3.3× | 12.4×+1.3× | 11.1×+0.3× | |
| Quick ratio | 7.1×-1.1× | 8.1×-0.9× | 9×-3.3× | 12.4×+1.3× | 11.1×+0.3× | |
| Cash ratio | 5.1×+1.8× | 3.2×+0.7× | 2.5×-4.7× | 7.2×+4.1× | 3.1×+1.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.59-29.9% | $2.27-4.5% | $2.38-21.1% | $3.01+17.9% | $2.55-16.6% | |
| Valuation | ||||||
| Market capitalization | $709.23M+89.4% | $346.09M-9.8% | $383.9M-5.5% | $406.13M+38.0% | $294.32M-28.3% | |
| Enterprise value | $641.43M+80.8% | $303.95M-14.2% | $354.1M+11.7% | $316.87M+15.4% | $274.54M-31.0% | |
| Price / book | 6.6×+3.7× | 2.5×+0.1× | 2.5×+0.1× | 2.3×0.0× | 2.3×-0.4× | |
| Free cash flow yield | -12.9%+8.5pp | -24.6%-1.5pp | -23.1%-2.4pp | -20.7%+6.5pp | -27.2%-7.5pp | |
| Earnings yield | -15.8%+9.4pp | -30.7%-3.0pp | -27.7%-2.8pp | -25%+7.2pp | -32.2%-11.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Aura Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Aura Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.